$ICLR · ICON PLC
ICON plc filed its Q3 2026 6-K, reporting revenue of $2.025B (-2.9% YoY), GAAP net income of $122.1M ($1.58 diluted EPS), and operating margin of 9.8%. The year-ago quarter included $465M in goodwill and non-financial asset impairments that drove a $284M net loss. The company executed $400M in share buybacks during the quarter and completed a $2.15B senior unsecured notes issuance to refinance existing secured and bridge debt.
- Q3 revenue $2.025B, down 2.9% YoY from $2.085B
- Q3 GAAP EPS $1.58 vs -$3.67 loss a year ago, when $465M in impairment charges hit
- Operating margin swung to 9.8% from -10.7% in Q3 2025
- Repurchased 2.36M shares for $400M in Q3; board boosted buyback authorization to $750M
- Completed $2.15B debt refinancing in August, repaying $2.15B of secured and bridge debt
Extended-hours last trade at $195.32, up 6.75% vs regular close of $182.98. The swing from a year-ago $284M net loss to $122M net income, combined with the aggressive $400M buyback and upsized $750M authorization, is driving the after-hours bid.
ICON's dramatic profit recovery — from impairment-driven losses to $122M net income — paired with a $750M buyback signals management confidence in the CRO cycle trough.
ICON's -2.9% revenue decline contrasts with the broader CRO sector's post-pandemic normalization; peers IQV and MEDP have also reported muted top-line growth as biotech funding remains selective.
Direct costs rose to 75.7% of revenue from 73.8% a year ago, compressing gross margin. Currency translation losses of $41M in the nine-month period signal FX exposure risk across 55-country operations.